A veteran pharma venture capital insider purchased 25,000 shares of Nuvation Bio as its new drug gains momentum. The insider's buy signals confidence in the company's pipeline. Nuvation Bio is developing therapies for oncology.
Tap to vote and see what everyone thinks.
Summary by ByteBrief
Parabilis Medicines raises $670M in IPO